Multiple sclerosis (MS) is a relatively common acquired chronic relapsing demyelinating disease involving the central nervous system. It is by definition disseminated not only in space (i.e multiple lesions), but also in time (i.e. lesions are of different age).
A number of clinical variants are recognised, each with specific imaging findings and clinical presentation. They include:
- classic multiple sclerosis (Charcot type)
- tumefactive multiple sclerosis
- (acute malignant) Marburg's type
- Schilder type (diffuse cerebral sclerosis)
- Balo concentric sclerosis (BCS)
This articles concerns itself primarily with classic (Charcot type) multiple sclerosis. The other variants are discussed separately.
Of note neuromyelitis optica (Devic disease) was considered a variant but is now recognised as a distinct entity.
Presentation is usually between adolescence and the sixth decade, with a peak at approximately 35 years of age 12. There is a strong, well recognised female predilection with a F:M ratio of 2-3:1.
Multiple sclerosis has a fascinating geographic distribution: it is rarely found in equatorial regions, with incidence gradually increasing with distance from the equator 12.
Clinical presentation is both highly variable acutely, as a result of varying plaque location as well as over time, with a number of patterns of longitudinal disease being described 11-12:
- most common (70% of cases)
- patients exhibit periodic symptoms with complete recovery (early on)
- approximately 85% of patients with relapsing-remitting MS eventually enter a secondarily progressive phase
- uncommon (10% of cases)
- patients do not have remissions, with neurological deterioration being relentless
- progressive with relapses
benign multiple sclerosis
- 15-50% of cases
- defined as patients who remain functionally active for over 15 years
As is evident from this list, there is overlap, and in some cases patients can drift from one pattern to another.
Upon presentation patients often have evidence of multiple previous asymptomatic lesions, and the diagnosis of multiple sclerosis can be strongly inferred. In other instances patients present with the first plaque. This is known as clinically isolated syndrome (CIS) and not all patients go on to develop MS.
Radiologically isolated syndrome (RIS) is another entity based on MRI brain findings which described as incidental white matter lesions suggestive of MS on imaging in a patient without associated clinical symptoms 17.
The exact aetiology is poorly known although it is believed to have both genetic and acquired contributory components. An infectious agent (EBV) or at least catalyst have long been suspected due to the geographic distribution and presence of clusters of cases, however no agent has as yet been firmly identified. Some authors also suggested that "chronic cerebrospinal venous insufficiency" can cause or exacerbate MS but this theory has not been proven by further investigations 15.
MS is believed to result from a cellular mediated autoimmune response against ones own myelin components, with loss of oligodendrocytes, with little or no axonal degeneration in acute phase; however, in late stage, loss of oligodendrocytes result in axonal degeneration.
Demyelination occurs in discrete foci, termed plaques which range in size from a few millimetres to a few centimeters and are typically perivenular.
Each lesion goes through three pathological stages:
early acute stage (active plaques)
- active myelin breakdown
- plaques appear pink and swollen
- plaques become paler in colour ("chalky")
- abundant macrophages
chronic stage (inactive plaques/gliosis)
- little or no myelin breakdown
- gliosis with associated volume loss
- appear grey/translucent
Patients serum IgG levels tend to be elevated and CSF analysis commonly shows oligoclonal bands.
- a strong association with HLA-DR2 class II has been identified 11
- Melkersson-Rosenthal syndrome: postulated
Plaques can occur anywhere in the central nervous system. They are typically ovoid in shape and perivenular in distribution.
CT features are usually non-specific, and significant change may be seen on MRI with an essentially normal CT scan. Features that may be present include:
- plaques can be homogeneously hypo attenuating 8, 11
- brain atrophy may be evident in with long standing chronic MS 5
- some plaques may show contrast enhancement in the active phase 7,11
MRI has revolutionised the diagnosis and surveillance of patients with MS. Not only can an MRI confirm the diagnosis (see McDonald MRI criteria for multiple sclerosis), but follow-up scans can assess response to treatment and try and determine the disease pattern.
- T2: lesions are typically hyperintense
- lesions are typically hyperintense
- very early sign is called "ependymal dot-dash sign": alternating small foci of hyperintensity along the callososeptal interface 16
- when these propagate centrifugally along the medullary venules and arranged perpendicular to lateral ventricles in triangular configuration (extending radially outward -best seen on parasagittal images), they are termed Dawson fingers
- FLAIR is more sensitive than T2 in detection of juxtacortical and periventricular plaques while T2 is more sensitive in infratentorial lesions
T1 C+ (Gd)
- active lesions show enhancement
- enhancement is often incomplete around the periphery (open ring sign)
- DWI/ADC: active plaques may demonstrate restricted diffusion 10-11
- NAA peaks may be reduced within plaques, which is the most common and remarkable finding
- Cho and lactate are found to be increased in the acute pathologic phase
- double inversion recovery DIR: a new sequence that suppress both CSF and white matter signal and better delineation of the plaques.
Location of the plaques can be infratentorial, deep white matter, periventricular, juxtacortical or mixed white matter-grey matter lesions.
Even on a single scan, some features are helpful in predicting relapsing-remitting vs. progressive disease. Features favouring progressive disease include:
- large numerous plaques
- hyperintense T1 lesions
Treatment and prognosis
The aim of treatment is twofold: to curtail progression (disease modifying agents) and symptomatic relief.
Steroids, interferon, monoclonal antibodies are all used. Discussion of individual agents is beyond the scope of this article. It is important to remember from an imaging perspective that the use of steroids can make an active lesion reduce in size and reduce enhancement.
Prognosis is variable and depends on the pattern of disease a pattern has (e.g. primary progressive carries a worse prognosis than relapsing-remitting).
In general, patients with relapsing-remitting MS will progress to secondary progressive disease in 10 years, and will require ambulatory aids (e.g. cane/wheelchair/frame) in another 5 to 15 years 12.
The differential diagnosis is dependent on the location and appearance of demyelination. For classic (Charcot type) MS the differential can be divided into intracranial and spinal involvement.
For intracranial disease the differential includes almost all other demyelinating disease as well as:
- CNS fungal infection (e.g. Cryptococcus neoformans) patients tend to be immunocompromised
- mucopolysaccharidosis (e.g. Hurler disease): congenital and occurs in a younger age group
- Marchiafava-bignami disease (for callosal lesions)
- Susac syndrome
- CNS manifestations of primary antiphospholipid syndrome 13
For spinal involvement the following should be considered:
- primary demyelinating disorders
- clinically isolated syndrome (CIS)
- radiologically isolated syndrome (RIS)
- multiple sclerosis (MS)
- neuromyelitis optica (NMO) (Devic disease)
- acute disseminated encephalomyelitis (ADEM) and acute haemorrhagic encephalomyelitis (AHEM)
- tumefactive demyelinating lesions
- transverse myelitis
- chronic inflammatory demyelinating polyneuropathy (CIDP)
- Guillain-Barre Syndrome (GBS)
- primary demyelinating disorders
- 1. Sheldon JJ, Siddharthan R, Tobias J et-al. MR imaging of multiple sclerosis: comparison with clinical and CT examinations in 74 patients. AJR Am J Roentgenol. 1985;145 (5): 957-64. AJR Am J Roentgenol (abstract) - Pubmed citation
- 2. Richards TL. Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy. AJR Am J Roentgenol. 1991;157 (5): 1073-8. AJR Am J Roentgenol (abstract) - Pubmed citation
- 3. Lövblad KO, Anzalone N, Dörfler A et-al. MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol. 2010;31 (6): 983-9. doi:10.3174/ajnr.A1906 - Pubmed citation
- 4. Caracciolo JT, Murtagh RD, Rojiani AM et-al. Pathognomonic MR imaging findings in Balo concentric sclerosis. AJNR Am J Neuroradiol. 2001;22 (2): 292-3. AJNR Am J Neuroradiol (full text) - Pubmed citation
- 5. Ge Y, Grossman RI, Udupa JK et-al. Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter. Radiology. 2001;220 (3): 606-10. doi:10.1148/radiol.2203001776 - Pubmed citation
- 6. Tan IL, Van schijndel RA, Pouwels PJ et-al. MR venography of multiple sclerosis. AJNR Am J Neuroradiol. 21 (6): 1039-42. AJNR Am J Neuroradiol (full text) - Pubmed citation
- 7. Maravilla KR, Weinreb JC, Suss R et-al. Magnetic resonance demonstration of multiple sclerosis plaques in the cervical cord. AJR Am J Roentgenol. 1985;144 (2): 381-5. AJR Am J Roentgenol (abstract) - Pubmed citation
- 8. Nesbit GM, Forbes GS, Scheithauer BW et-al. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology. 1991;180 (2): 467-74. Radiology (abstract) - Pubmed citation
- 9. Miller DH, Grossman RI, Reingold SC et-al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 1998;121 ( Pt 1) : 3-24. Brain (link) - Pubmed citation
- 10. Nusbaum AO, Lu D, Tang CY et-al. Quantitative diffusion measurements in focal multiple sclerosis lesions: correlations with appearance on TI-weighted MR images. AJR Am J Roentgenol. 2000;175 (3): 821-5. AJR Am J Roentgenol (full text) - Pubmed citation
- 11. Kornienko VN, Pronin IN. Diagnostic Neuroradiology. Springer Verlag. (2008) ISBN:3540756523. Read it at Google Books - Find it at Amazon
- 12. Brust JC. Current diagnosis & treatment in neurology. McGraw-Hill Medical. (2006) ISBN:0071423664. Read it at Google Books - Find it at Amazon
- 13. Stosic M, Ambrus J, Garg N et-al. MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J. Neurol. 2010;257 (1): 63-71. doi:10.1007/s00415-009-5264-6 - Pubmed citation
- 14. Wattjes MP, Lutterbey GG, Gieseke J et-al. Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol. 2007;28 (1): 54-9. Pubmed citation
- 15. Garaci FG, Marziali S, Meschini A et-al. Brain hemodynamic changes associated with chronic cerebrospinal venous insufficiency are not specific to multiple sclerosis and do not increase its severity. Radiology. 2012;265 (1): 233-9. doi:10.1148/radiol.12112245 - Pubmed citation
- 16. Lisanti CJ, Asbach P, Bradley WG. The ependymal "Dot-Dash" sign: an MR imaging finding of early multiple sclerosis. AJNR Am J Neuroradiol. 2005;26 (8): 2033-6. AJNR Am J Neuroradiol (full text) - Pubmed citation
- 17. Okuda DT, Mowry EM, Beheshtian A et-al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72 (9): 800-5. doi:10.1212/01.wnl.0000335764.14513.1a - Pubmed citation
- 18. Janardhan V, Suri S, Bakshi R. Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening. Radiology. 2007;244 (3): 823-31. doi:10.1148/radiol.2443051171 - Pubmed citation